Evidence map›Paper›PMID 31375105›Full record

ArticleBMC medical genomics2019

Identification of single nucleotide variants using position-specific error estimation in deep sequencing data.

Dimitrios Kleftogiannis, Marco Punta, Anuradha Jayaram, Shahneen Sandhu, Stephen Q Wong, Delila Gasi Tandefelt, Vincenza Conteduca, Daniel Wetterskog, Gerhardt Attard, Stefano Lise

Abstract read
In one paragraph

Article in BMC medical genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dimitrios KleftogiannisCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Marco PuntaCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Anuradha JayaramUCL Cancer Institute, University College London, London, UK.
Shahneen SandhuPeter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.
Stephen Q WongPeter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.
Delila Gasi TandefeltDepartment of Urology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Vincenza ConteducaDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014, Meldola, Italy.
Daniel WetterskogUCL Cancer Institute, University College London, London, UK.
Gerhardt AttardUCL Cancer Institute, University College London, London, UK. g.attard@ucl.ac.uk.
Stefano LiseCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK. Stefano.Lise@icr.ac.uk.ORCID 0000-0003-4472-6893

Funding

Cancer Research UK 22744Cancer Research UK A13239Prostate Cancer UK PG12-49Wellcome TrustWellcome Trust 105104/Z/14/
6 · The paper itself

Abstract

backgroundTargeted deep sequencing is a highly effective technology to identify known and novel single nucleotide variants (SNVs) with many applications in translational medicine, disease monitoring and cancer profiling. However, identification of SNVs using deep sequencing data is a challenging computational problem as different sequencing artifacts limit the analytical sensitivity of SNV detection, especially at low variant allele frequencies (VAFs).

methodsTo address the problem of relatively high noise levels in amplicon-based deep sequencing data (e.g. with the Ion AmpliSeq technology) in the context of SNV calling, we have developed a new bioinformatics tool called AmpliSolve. AmpliSolve uses a set of normal samples to model position-specific, strand-specific and nucleotide-specific background artifacts (noise), and deploys a Poisson model-based statistical framework for SNV detection.

resultsOur tests on both synthetic and real data indicate that AmpliSolve achieves a good trade-off between precision and sensitivity, even at VAF below 5% and as low as 1%. We further validate AmpliSolve by applying it to the detection of SNVs in 96 circulating tumor DNA samples at three clinically relevant genomic positions and compare the results to digital droplet PCR experiments.

conclusionsAmpliSolve is a new tool for in-silico estimation of background noise and for detection of low frequency SNVs in targeted deep sequencing data. Although AmpliSolve has been specifically designed for and tested on amplicon-based libraries sequenced with the Ion Torrent platform it can, in principle, be applied to other sequencing platforms as well. AmpliSolve is freely available at https://github.com/dkleftogi/AmpliSolve .

Indexed as

BenchmarkingCirculating Tumor DNAHigh-Throughput Nucleotide SequencingHumansPolymorphism, Single NucleotideReproducibility of ResultsCirculating Tumor DNACancer genomicsDeep sequencingError correctionIon torrentLiquid biopsiesNext generation sequencing (NGS)Targeted sequencingVariant calling

Identifiers

PMID31375105
PMCPMC6679440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.